Hypertensive Disease Study (1962):
Mebutamate is reported to lower the blood pressure and, at the same time, not decrease the cardiac output. The action (vasodilation) is said to be mediated through the central nervous system by action on certain areas of the hypothalamus and medulla, not by direct effect on ganglia or blood vessels. Because of the reported action and effects of mebutamate, a preliminary clinical evaluation was undertaken to determine 1) the effectiveness of this drug in the treatment of hypertensive patients, and 2) any side effects which might occur with its use.
Hypertensive Disease Study Conclusion:
It is concluded that mebutamate is an effective anti hypertensive drug; however the dosage should be adjusted according to the requirements of the individual patient. It does not produce postural hypotension or interfere with the physiologic mechanisms which regulate the blood pressure. It can be used safely with other forms of therapy required for concomitant disease. Mebutamate is effective within a similar range of cases as reserpine but does not produce the severe side effects associated with the latter.
Mebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a sedative. Side effects include dizziness and headaches. This compound belongs to the class of organic compounds known as carbamate esters.
|Depressants | Link to this page|